Trial · NCT07913412
High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal Melanoma: Modern Radiation Techniques and Outcomes
NCT07913412, Recruiting, University Hospital, Essen
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal Melanoma: Modern Radiation Techniques and Outcomes. Trials, record NCT07913412. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913412
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal Melanoma: Modern Radiation Techniques and Outcomes
- NCT number
- NCT07913412
- Status
- Recruiting
- Enrollment
- 250 participants, estimated
- Lead sponsor
- University Hospital, Essen
- Conditions
- Uveal Melanoma, High-risk Uveal Melanoma, Prominent Uveal Melanoma
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Local control | At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months. | Local control |
| Primary | Function: Visual acuity: | At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months. | Visual function assessed separately for each eye. Visual acuity: decimal scale,range 2,0 - 0,01: decimal acuity scale |
| Primary | Quality of Life, ophthalmic cancer-specific quality of life | At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months. | Quality of Life, ophthalmic cancer-specific quality of life 1\) EORTC QLQ-OPT30 (ophthalmic cancer-specific quality of life): Scores range from 0-100; higher scores indicate greater visual impairment, ocular symptoms, and functional difficulties. |
| Primary | Progression Free Survival | At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months. | Progression Free Survival |
| Primary | Overall Survival | At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months. | Overall Survival |
| Primary | Function: Visual acuity: | At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months. | Visual function assessed separately for each eye. Visual acuity: decimal scale,range 2,0 - 0,01: decimal acuity scale; furthermore, 1.Count-fingers, 2.hand-motion and 3.light-perception categories are recorded separately when acuity cannot be quantified: for each item: value yes / no |
| Primary | Function: Visual field | At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months. | Visual field: Automated perimetry, Visual Field Index (VFI, %): 0 % - 100%, |
| Primary | Quality of Life general quality of life | At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months. | EORTC QLQ-C30 (general quality of life): Scores range from 0-100; A) higher scores indicate better functioning/global quality of life B) symptom scores: indicate greater symptom burden on symptom scales. |
| Primary | Function: Retinal Nerve Fiber Layer | At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months. | Optical coherence tomography (OCT): Peripapillary retinal nerve fiber layer (RNFL) thickness, measured in µm and classified in percentiles (regarding normal values) |
| Primary | Cornea | At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months. | corneal outcome: thickness measured in µm |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 36230660 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913412
GET https://conductscience.org/api/trials/v1/NCT07913412/registered